Symphony Evolution

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Symphony Evolution sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 3 completed early-phase tilt top decile by trial count

Symphony Evolution: 10 sponsored US clinical trials, none currently recruiting.

Symphony Evolution sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignancies, with 1 trials.

Top-decile sponsor footprint

Symphony Evolution ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

3 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (30.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 1

Maintenance Study on the Long Term Safety of XL999

NCT00955084
TERMINATED Phase 1

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

NCT00491699
TERMINATED Phase 2

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

NCT00322673
COMPLETED Phase 2

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

NCT00312780
TERMINATED Phase 2

Study of XL999 in Patients With Multiple Myeloma

NCT00304590
TERMINATED Phase 2

Study of XL999 in Patients With Previously Treated Ovarian Cancer

NCT00277290
TERMINATED Phase 2

Study of XL999 in Patients With Metastatic Colorectal Cancer

NCT00277303
TERMINATED Phase 2

Study of XL999 in Patients With Non-small Cell Lung Cancer

NCT00277329
TERMINATED Phase 2

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

NCT00277316
COMPLETED Phase 1

Study of XL999 in Adults With Solid Tumors

NCT00104117

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 7

Therapeutic Areas

Advanced Malignancies 1

How the Symphony Evolution early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 3 completed (30%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Advanced Malignancies (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Symphony Evolution: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Symphony Evolution sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Symphony EvolutionAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Symphony Evolution sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Symphony Evolution sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Symphony Evolution page

10 registered trials is a research-attention snapshot, not an endorsement of Symphony Evolution or any single study.

  • None of Symphony Evolution's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Advanced Malignancies is the condition Symphony Evolution studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignancies trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Symphony Evolution pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.